France
· Delayed Price · Currency is EUR MedinCell Statistics
Total Valuation
MedinCell has a market cap or net worth of EUR 500.31 million. The enterprise value is 545.55 million.
| Market Cap | 500.31M |
| Enterprise Value | 545.55M |
Important Dates
The next estimated earnings date is Tuesday, December 10, 2024.
| Earnings Date | Dec 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MedinCell has 29.09 million shares outstanding. The number of shares has increased by 12.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 29.09M |
| Shares Change (YoY) | +12.83% |
| Shares Change (QoQ) | +3.98% |
| Owned by Insiders (%) | 15.85% |
| Owned by Institutions (%) | 27.02% |
| Float | 20.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.92 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.79 |
| EV / Sales | 45.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -44.55 |
Financial Position
The company has a current ratio of 1.66
| Current Ratio | 1.66 |
| Quick Ratio | 1.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.28 |
| Interest Coverage | -4.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -39.49% |
| Return on Capital (ROIC) | -66.61% |
| Revenue Per Employee | 89,142 |
| Profits Per Employee | -186,851 |
| Employee Count | 134 |
| Asset Turnover | 0.36 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +183.33% in the last 52 weeks. The beta is 1.18, so MedinCell's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +183.33% |
| 50-Day Moving Average | 16.00 |
| 200-Day Moving Average | 14.02 |
| Relative Strength Index (RSI) | 57.19 |
| Average Volume (20 Days) | 78,464 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedinCell had revenue of EUR 11.95 million and -25.04 million in losses. Loss per share was -0.88.
| Revenue | 11.95M |
| Gross Profit | 11.95M |
| Operating Income | -20.94M |
| Pretax Income | -24.95M |
| Net Income | -25.04M |
| EBITDA | -20.05M |
| EBIT | -20.94M |
| Loss Per Share | -0.88 |
Balance Sheet
The company has 19.46 million in cash and 64.71 million in debt, giving a net cash position of -45.25 million or -1.56 per share.
| Cash & Cash Equivalents | 19.46M |
| Total Debt | 64.71M |
| Net Cash | -45.25M |
| Net Cash Per Share | -1.56 |
| Equity (Book Value) | -40.82M |
| Book Value Per Share | -1.40 |
| Working Capital | 10.79M |
Cash Flow
In the last 12 months, operating cash flow was -11.92 million and capital expenditures -324,000, giving a free cash flow of -12.25 million.
| Operating Cash Flow | -11.92M |
| Capital Expenditures | -324,000 |
| Free Cash Flow | -12.25M |
| FCF Per Share | -0.42 |
Margins
Gross margin is 100.00%, with operating and profit margins of -175.30% and -209.61%.
| Gross Margin | 100.00% |
| Operating Margin | -175.30% |
| Pretax Margin | -208.87% |
| Profit Margin | -209.61% |
| EBITDA Margin | -167.82% |
| EBIT Margin | -175.30% |
| FCF Margin | -102.52% |
Dividends & Yields
MedinCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.83% |
| Shareholder Yield | -12.83% |
| Earnings Yield | -5.12% |
| FCF Yield | -2.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedinCell has an Altman Z-Score of -0.59. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.59 |
| Piotroski F-Score | n/a |